Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows opioid growth factor safe for treatment of pancreatic cancer

21.04.2004


A booster dose of a substance already found in the body appears to be safe and non-toxic for the treatment of pancreatic cancer, and shows signs of arresting pancreatic cancer cell growth in patients, Penn State College of Medicine researchers report.



"Our previous laboratory and animal studies showed that opioid growth factor, called OGF, can markedly slow down the proliferation of pancreatic cancer cells," said Ian S. Zagon, Ph.D., professor of neural and behavioral sciences, Penn State College of Medicine. "Now, in this first study of OGF in people, we’ve shown that administering it to supplement the body’s own supply is not toxic and may help patients with this almost invariably fatal disease."

The article titled, "Treatment of advanced pancreatic cancer with opioid growth factor: Phase I," appeared in the March 2004 issue of the journal Anti-Cancer Drugs.


Cancer of the pancreas, a gland in the abdomen that makes insulin and other hormones, is the fourth leading cause of cancer death. Because pancreatic cancer is usually diagnosed after it has spread to other areas of the body, as many as 98 percent of people who are diagnosed with pancreatic cancer will die from it, and only 4 percent will live more than five years.

In laboratory studies, Zagon and his team discovered that OGF, which is involved in suppression of pain in the nervous system, also controls the production of some cells, both healthy and abnormal. Pancreatic cancer cells have OGF receptors that, when bound with OGF, inhibit additional cancer cell growth. Because cancer cells reproduce so quickly, the body can’t produce enough OGF to bind all of the receptors, so cancer cell growth continues unimpeded. Zagon’s laboratory work suggested that providing enough OGF in the body could bind the OGF receptors, inhibit cancer cell proliferation, and give the body’s own defenses time to battle the disease.

For the Phase I clinical study, sponsored by the National Institutes of Health, Zagon’s collaborator Jill Smith, M.D., professor of medicine, Penn State College of Medicine, enrolled 21 patients with advanced, inoperable, pancreatic cancer. In one group, OGF was administered intravenously in a saline solution over 30 minutes once per week. Investigators tested seven different doses ranging from 25 micrograms/kilogram (ìg/kg) to 250 ìg/kg. Other patients enrolled in the study were taught to self-administer 50 ìg/kg doses of OGF twice per day via injection. Before, during and after intravenous infusion and the initial injected doses, vital signs were monitored and laboratory values were recorded. The study protocol was approved by the Institutional Review Board at Penn State Milton S. Hershey Medical Center under federal regulations and was conducted in the National Institutes of Health-funded Penn State General Clinical Research Center.

The investigators found that the maximum tolerated dose of OGF administered intravenously was 250 ìg/kg. At 250 ìg/kg, two patients experienced mild symptoms of toxicity, the most severe of which was temporary hypotension, or low blood pressure.

In a second part of the study, 10 patients were treated with 250 ìg/kg intravenous infusions of OGF, this time delivered over 45 minutes. Because the timing of drug delivery was extended, there were no incidents of toxicity. Six other patients were treated with 50 ìg/kg OGF injections twice per day.

Results showed that, unlike the chemotherapeutic agents often used to treat pancreatic cancer, OGF did not cause white blood cell, platelet or iron counts to drop, and did not cause gastrointestinal problems. Nor were there side effects such as hair loss, nausea or loss of appetite.

Quality of life surveys administered before and during the study showed that patients had improved social interaction and alertness behavior, improved sleep and rest, mobility and communication. Pain and depression surveys showed a diminishment in pain scores at certain points during the therapy, and that OGF did not induce depression, but may have actually prevented the development of depression in the terminally-ill patients.

"Although this study was not intended to examine tumor response or survival, our preliminary results showed two patients with spread of the cancer to the liver responded with loss of metastases, and survival was increased from 5.6 months under the typical treatment with gemcitabine, to 9.1 months with OGF," Zagon said. "Some patients survived from 21 to 23 months."

Zagon said preclinical studies of OGF indicate that it may be useful in the treatment of other cancers that rely on OGF for growth such as colon, head and neck, kidney and developing nervous system.

The investigators are currently enrolling patients in a larger, phase II study of OGF for the treatment of pancreatic cancer sponsored by the National Institutes of Health. For more information or to be evaluated for inclusion in the trial, contact Sandra Bingaman, R.N., research study coordinator, at (717) 531-8108.

Co-authors on the study were: Jill P. Smith, M.D., Robert L. Conter, M.D., Sandra I. Bingaman, Harold A. Harvey, M.D., David T. Mauger, Ph.D., Mejdi Ahmad, M.D., Lawrence M. Demers, Ph.D., Wayne B. Stanley, and Patricia J. McLaughlin, Ph.D., Penn State College of Medicine, Penn State Milton S. Hershey Medical Center.

Valerie Gliem | EurekAlert!
Further information:
http://www.psu.edu/

More articles from Health and Medicine:

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

nachricht Overdosing on Calcium
19.06.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Creating a new composite fuel for new-generation fast reactors

20.06.2018 | Materials Sciences

Game-changing finding pushes 3D-printing to the molecular limit

20.06.2018 | Materials Sciences

Could this material enable autonomous vehicles to come to market sooner?

20.06.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>